GHK-Cu

Telehealth medication prices per month, as each provider states them

GHK-Cu (copper peptide tripeptide-1) is a naturally occurring plasma copper complex with broad tissue-remodelling activity. It is one of the most extensively researched peptides for skin health, wound healing, and collagen synthesis. Research has explored its effects across dermatological, cosmetic, and systemic contexts, including roles in joint tissue maintenance and anti-inflammatory signalling. GHK-Cu is a component of the GLOW research blend (GHK-Cu + BPC-157 + TB-500), a combination studied in research contexts for synergistic effects on tissue repair, collagen synthesis, and wound healing across multiple tissue types. Research has also explored GHK-Cu in longevity contexts, including its relationship to declining plasma GHK-Cu levels with age and proposed effects on gene expression relevant to cellular health. Providers offering GHK-Cu — including telehealth platforms — can be found via the PeptideBase directory. GHK-Cu dosage and administration: No human clinical trial has established a definitive dosage protocol for GHK-Cu across its various research applications. Topical formulations are the most widely studied delivery route for dermatological applications — concentrations of 1–5% in serums or creams are used in cosmetic research contexts, with daily or twice-daily application. Injectable GHK-Cu is investigated in research settings, with subcutaneous administration as the primary delivery route; no validated human dosing protocol has been established for any injectable GHK-Cu application. Intravenous GHK-Cu administration has been explored in some research contexts, though this route is less common than subcutaneous injection. Plasma GHK-Cu levels naturally decline with age — from approximately 200 ng/mL in young adults to below detection in those over 60 — which has driven research interest in supplemental GHK-Cu for age-related tissue maintenance. All dosing contexts referenced here are from research literature only; no approved clinical dosing guidelines exist for GHK-Cu in any jurisdiction. Why is GHK-Cu blue: GHK-Cu's characteristic blue color comes from the copper(II) chelation complex. The tripeptide GHK (glycyl-histidyl-lysine) forms a coordination complex with Cu²⁺ ions — the oxidized form of copper — producing a blue-to-blue-green hue typical of copper(II) coordination chemistry. This coloration is normal and expected in correctly formulated GHK-Cu solutions; the intensity of blue indicates proper copper binding. A colorless or off-white GHK-Cu solution may indicate inadequate copper incorporation. The same copper chelation responsible for the blue color is also central to GHK-Cu's proposed mechanisms of action, including its roles in collagen synthesis activation and antioxidant activity. Where to get GHK-Cu: GHK-Cu is available through several channels depending on the intended use. Topical GHK-Cu formulations (serums, creams, 1–5% concentration) are sold as cosmetic ingredients directly to consumers without prescription requirements. Injectable and subcutaneous GHK-Cu for research applications is available through compounding pharmacies — typically requiring a prescription and physician involvement — and through research chemical suppliers. Availability is not the same as legal eligibility: GHK-Cu is not on the FDA 503A bulks list, and its removal from the interim Category 2 list in April 2026 followed the withdrawal of its nomination — which does not authorize compounding. No lawful 503A compounding pathway currently exists for it. Some telehealth platforms offering peptide protocols include GHK-Cu alongside BPC-157 and TB-500 in connective tissue and skin-focused research stacks. The PeptideBase directory lists providers carrying GHK-Cu by location and provider type. Copper peptides before and after: What does GHK-Cu research show? Controlled studies on GHK-Cu skincare formulations document measurable changes in skin parameters over 8–16 weeks of consistent topical use. Histological analysis in published research has shown increases in skin thickness and dermal collagen density, reductions in fine lines and surface roughness, and improvements in wound healing speed relative to placebo-treated skin. A commonly cited 12-week study found statistically significant improvements in skin laxity and fine line depth compared to vehicle controls. The "before and after" pattern observed in copper peptide research reflects the compound's multi-pathway activity — collagen synthesis stimulation, matrix metalloproteinase modulation, and antioxidant copper delivery all contribute to cumulative dermal remodelling over weeks. Results in published studies are modest relative to ablative procedures but consistent across multiple independent research groups. Topical GHK-Cu products available over the counter (serums, creams) contain the tripeptide complex at concentrations typically ranging from 1–5%; compounded injectable or subcutaneous formulations require a prescription through a licensed provider. Copper peptides and hair loss GHK-Cu has been studied in androgenetic alopecia and hair follicle biology contexts. Research indicates it stimulates stem cell activity in the hair follicle bulge region, promotes angiogenesis through upregulation of vascular endothelial growth factor (VEGF) — increasing blood supply to follicles — and prolongs the anagen (active growth) phase of the hair cycle. In vitro and animal studies have shown GHK-Cu can increase hair follicle size and density. Human studies are limited, but topical GHK-Cu has been examined as a potential adjunct in hair loss contexts, particularly for diffuse thinning where scalp microcirculation and follicle support are relevant mechanisms. It is sometimes applied alongside minoxidil in cosmetic scalp formulations, with the copper peptide proposed to address the collagen and vascular aspects of follicle maintenance that minoxidil does not directly target. Topical GHK-Cu for hair use is available over the counter in scalp serums and hair density products; no injectable form specific to hair loss treatment exists. [Women's health addendum] Human evidence for GHK-Cu is limited to topical/cosmetic skin studies; there is no systemic or injectable human safety or efficacy data. Marketing claims that GHK-Cu "reverses menopausal skin and hair aging" systemically, or supports bone/metabolic outcomes in menopause, are not supported by the published literature, which is topical-application only and predominantly from the discoverer's own research group.

2 published offers · 2 of 29 providers with a result publish a price (69 in the directory) · checked 3 Oct 2026 · how this is computed · eligibility is decided by a licensed prescriber · not medical advice